SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astec Lifesciences gains on resuming operations at Dombivili Plant

29 May 2014 Evaluate

Astec Lifesciences is currently trading at Rs. 46.50, up by 0.15 points or 0.32% from its previous closing of Rs. 46.35 on the BSE.

The scrip opened at Rs. 48.50 and has touched a high and low of Rs. 48.50 and Rs. 46.35 respectively. So far 1775 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 48.20 on 25-Apr-2014 and a 52 week low of Rs. 15.60 on 30-Jul-2013.

Last one week high and low of the scrip stood at Rs. 47.90 and Rs. 42.70 respectively. The current market cap of the company is Rs. 86.16 crore.

The promoters holding in the company stood at 58.05% while Non-Institutions held 41.95% stake in the company.

Astec Lifesciences has resumed its manufacturing activities at Dombivili Plant on May 13, 2014 after getting permission from MPCB. Earlier, the company had received order from MPCB for temporary suspension of operations at Dombivili Plant. Astec LifeSciences having its plant at Plot No- F-39, MIDC, Phase II, Dombivili, District- Thane is one of the 22 companies which have received an order for temporary suspension of operations.

National Green Tribunal (NGT) based on an appeal filed by NGO Vanashakti, has been seeking clarifications from MPCB regarding contamination of the Ulhas River.

Astec LifeSciences is a producer of agrochemicals and pharmaceutical intermediates. The company manufactures a wide range of Agrochemical active ingredients and pharmaceutical intermediates.

 

Astec Lifesciences Share Price

726.50 -22.90 (-3.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
UPL 665.00
PI Industries 3144.45
Bayer CropScience 4900.45
Sharda Cropchem 1109.70
Sumitomo Chemical 441.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×